Get the Stockscreener App
0.80
3.15%
-0.026
After Hours:
.80
Mdxhealth Sa stock is traded at $0.80, with a volume of 912.43K.
It is down -3.15% in the last 24 hours and down -64.91% over the past month.
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.
See More
Previous Close:
$0.826
Open:
$0.83
24h Volume:
912.43K
Relative Volume:
2.08
Market Cap:
$41.09M
Revenue:
$107.88M
Net Income/Loss:
$-33.52M
P/E Ratio:
-1.1926
EPS:
-0.6708
Net Cash Flow:
$-11.94M
1W Performance:
-10.41%
1M Performance:
-64.91%
6M Performance:
-75.90%
1Y Performance:
-61.17%
1-Day Range:
$0.80
$0.84
1-Week Range:
$0.80
$0.95
52-Week Range:
$0.68
$5.33
Mdxhealth Sa Stock (MDXH) Company Profile
Compare MDXH vs TMO, DHR, IDXX, WAT, A
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MDXH
Mdxhealth Sa
|
0.80 | 42.43M | 107.88M | -33.52M | -11.94M | -0.6708 |
TMO
Thermo Fisher Scientific Inc
|
448.28 | 167.00B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
172.00 | 122.68B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
559.37 | 43.63B | 4.45B | 1.10B | 1.06B | 13.59 |
WAT
Waters Corp
|
342.37 | 33.48B | 3.77B | 449.25M | 240.68M | 7.8556 |
A
Agilent Technologies Inc
|
114.96 | 32.44B | 7.07B | 1.29B | 993.00M | 4.5355 |
Mdxhealth Sa Stock (MDXH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-17-25 | Initiated | Craig Hallum | Buy |
| Oct-31-24 | Initiated | Lake Street | Buy |
| May-31-23 | Initiated | TD Cowen | Outperform |
| Jul-18-22 | Resumed | Oppenheimer | Outperform |
Mdxhealth Sa Stock (MDXH) Latest News
MDxHealth to Shut Down Resolve UTI Business - Orange County Business Journal
MDxHealth SA (MDXH) Stock Analysis: -3.98% Loss — Key Levels 2026-05-21Fair Value Gap - Newser
Mdxhealth Refocuses on Prostate Franchise Amid Headwinds - The Globe and Mail
MDxHealth SA (MDXH) Stock Analysis: +4.85% Gain — What to Watch 2026-05-20Momentum ETF - Newser
Earnings call transcript: MDxHealth Q1 2026 sees significant stock drop amid earnings miss - Investing.com
MDxHealth SA (MDXH) Slips -1.62%, Testing $0.84 Support 2026-05-18Verified Signals - Newser
MDxHealth SA (MDXH) Q1 2026 Earnings: Miss Sparks ConcernCrowd Trend Signals - Newser
MDxHealth SA (MDXH) Q1 2026 Results Fall Short — EPS $-0.17, Revenue $N/ADividend Cut Risk - Newser
MDxHealth SA stock (US55278X1072): cancer diagnostics specialist back in focus after capital raise - AD HOC NEWS
MDxHealth SA (MDXH) Q1 2026 Earnings Miss: EPS $-0.19 vs $-0.15 ExpectedNCAV - Newser
MDxHealth Exits UTI Business Amid Medicare Reimbursement Dispute - HarianBasis.co
MDxHealth S.A. (NASDAQ:MDXH) Q1 2026 Earnings Call Transcript - Insider Monkey
MDxHealth (MDXH) Q1 Loss Near US$8.9 Million Reinforces Bearish Profitability Concerns - simplywall.st
MDXH Sets New Revenue Forecast Excluding Resolve, Anticipates St - GuruFocus
MDXH Maintained by Lake Street -- Price Target Lowered to $5.00 - GuruFocus
Mdxhealth Earnings Call: Prostate Pivot Amid Pressure - TipRanks
MDXH Maintained by TD Cowen -- Price Target Lowered to $1.50 - GuruFocus
MDXH Faces Challenges Amid Strategic Revisions and Medicare Disp - GuruFocus
MDxHealth SA Stock 12‑Month Price Target Cut to $3.9, Implies 100% Upside - TradingView
MDxHealth to exit the Resolve mdx business - TipRanks
MDxHealth price target lowered to $4 from $7 at BTIG - TipRanks
MDxHealth SA Stock 12‑Month Price Target Cut to $4.7, Implies 141% Upside - TradingView
TD Cowen cuts MDxHealth stock price target on Medicare dispute By Investing.com - Investing.com Australia
TD Cowen cuts MDxHealth stock price target on Medicare dispute - Investing.com
MDXH Maintained by BTIG -- Price Target Lowered to $4.00 - GuruFocus
Dow Jumps Over 250 Points; US Retail Sales Increase In April - Benzinga
MDxHealth SA stock (US55278X1072): Strong Q1 results amid strategic shift - AD HOC NEWS
MDxHealth SA Stock 12‑Month Price Target Cut to $5.7, Implies 192% Upside - TradingView
MDxHealth SA Stock 12‑Month Price Target Cut to $6.8, Implies 249% Upside - TradingView
MDxHealth SA (MDXH) Q1 2026 Earnings Call Highlights: Revenue Su - GuruFocus
MDxHealth Q1 Earnings Call Highlights - Inkl
Mdxhealth exits Texas Resolve lab after $10.4M Medicare recoupment - Stock Titan
MDXH Reports Strong Q1 Results Amid Strategic Business Changes - GuruFocus
MDXH: Exited UTI business, focusing on AI-driven prostate cancer diagnostics with 20–26% growth outlook - TradingView
MDXH: Exited UTI business, core cancer revenue up 11%, 2026 guidance set at $110–$115 million - TradingView
Earnings call transcript: MDxHealth Q1 2026 results miss forecasts, stock steady - Investing.com
Mdxhealth Exits Resolve Business, Refocuses on Prostate Cancer as Q1 2026 Revenue Rises 13% - TipRanks
MDxHealth Reports Q1 2026 Results: Full Earnings Call Transcript - Benzinga
Mdxhealth reports Q1-2026 results - marketscreener.com
MDxHealth (NASDAQ: MDXH) posts Q1 2026 growth and issues new 2026 guidance - Stock Titan
Mdxhealth Reports Q1-2026 Results - The Manila Times
MDxHealth reports Q1 EPS (17c) vs. (19c) last year - TipRanks
MSN Money - MSN
MDxHealth SA expected to post a loss of 15 cents a shareEarnings Preview - TradingView
Number of shareholders of MDxHealth SA – NASDAQ:MDXH - TradingView
MDXH SEC FilingsMdxhealth Sa 10-K, 10-Q, 8-K Forms - Stock Titan
Press Release: Mdxhealth to Release First Quarter 2026 Financial Results on May 13 - Moomoo
Mdxhealth Sa Stock (MDXH) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.72%
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):